Trial · NCT02278328

MEG Study of Acute STX209 Effects in ASD

NCT02278328, Early phase 1, Completed, Timothy Roberts; results first posted 2019-10-21

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. MEG Study of Acute STX209 Effects in ASD. Trials, record NCT02278328. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02278328

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: MEG Study of Acute STX209 Effects in ASD
NCT number: NCT02278328
Status: Completed
Phases: Early phase 1
Enrollment: 25 participants, actual
Lead sponsor: Timothy Roberts
Conditions: Autism Disorder
Interventions: STX209 (15mg), placebo, STX209 (30mg)
First posted: 2014-10-30
Last updated: 2019-10-21
Results first posted: 2019-10-21

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	M50 Latency (Left Hemisphere)	1 hour per intervention followed by a 1 week washout for a total of three weeks	The latency of the M50 auditory evoked response component arising from the left cerebral hemisphere
Primary	M50 Latency (Right Hemisphere)	1 hour per intervention followed by a 1 week washout for a total of three weeks	The latency of the M50 auditory evoked response component arising from the right cerebral hemisphere
Primary	Steady State Inter Trial Coherence (Left Hemisphere)	1 hour per intervention followed by a 1 week washout for a total of three weeks	The inter trial coherence (ITC) of auditory steady state response arising from the left cerebral hemisphere
Primary	Steady State Inter Trial Coherence (Right Hemisphere)	1 hour per intervention followed by a 1 week washout for a total of three weeks	The inter trial coherence (ITC) of auditory steady state response arising from the right cerebral hemisphere
Primary	GABA (Left Hemisphere)	1 hour per intervention followed by a 1 week washout for a total of three weeks	GABA/Cr ratio arising from a voxel in the left superior temporal gyrus

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	M50 Latency (Left Hemisphere)	1 hour per intervention followed by a 1 week washout for a total of three weeks	For placebo and 15mg dose, 1 case each was unavailable due to artifact. At 30mg dose, 2 cases were unevaluable due to artifact	ms	MEAN
PRIMARY	M50 Latency (Right Hemisphere)	1 hour per intervention followed by a 1 week washout for a total of three weeks	For placebo and 15mg dose, 1 case each was unavailable due to artifact. At 30mg dose, 4 cases were unevaluable due to artifact	ms	MEAN
PRIMARY	Steady State Inter Trial Coherence (Left Hemisphere)	1 hour per intervention followed by a 1 week washout for a total of three weeks	For placebo, 3 cases and for 15mg and 30mg doses, 1 case each was unevaluable due to artifact.	unitless	MEAN
PRIMARY	Steady State Inter Trial Coherence (Right Hemisphere)	1 hour per intervention followed by a 1 week washout for a total of three weeks	For placebo, 3 cases and for 15mg dose and 30mg doses, 1 case each was unevaluable due to artifact.	unitless	MEAN
PRIMARY	GABA (Left Hemisphere)	1 hour per intervention followed by a 1 week washout for a total of three weeks	For placebo, 5 cases were unevaluable. For 15mg, 7 cases were unevaluable. For 30mg, 4 cases were unevaluable	ratio	MEAN

Source ClinicalTrials.gov

Results by group15

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
M50 Latency (Left Hemisphere)	All Participants	Post placebo	90.9	Standard Deviation 13.8	ms
M50 Latency (Left Hemisphere)	All Participants	Post-15mg dose	87.4	Standard Deviation 16.9	ms
M50 Latency (Left Hemisphere)	All Participants	Post-30mg dose	89.3	Standard Deviation 13.5	ms
M50 Latency (Right Hemisphere)	All Participants	Post-placebo	95.1	Standard Deviation 21.7	ms
M50 Latency (Right Hemisphere)	All Participants	Post-15mg dose	87.8	Standard Deviation 8.6	ms
M50 Latency (Right Hemisphere)	All Participants	Post-30mg dose	93.8	Standard Deviation 23.6	ms
Steady State Inter Trial Coherence (Left Hemisphere)	All Participants	Post-placebo	.253	Standard Deviation .134	unitless
Steady State Inter Trial Coherence (Left Hemisphere)	All Participants	Post-15mg dose	.239	Standard Deviation .111	unitless
Steady State Inter Trial Coherence (Left Hemisphere)	All Participants	Post-30mg dose	.244	Standard Deviation .116	unitless
Steady State Inter Trial Coherence (Right Hemisphere)	All Participants	Post-placebo	.324	Standard Deviation .178	unitless

1 to 10 of 15Source ClinicalTrials.gov

See all 15 results by group

Participant flow63

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Neuropsych Screening	STARTED	A. Placebo Then 15mg Then 30mg	10
Neuropsych Screening	STARTED	B. 15mg Then Placebo Then 30mg	7
Neuropsych Screening	STARTED	C. 15mg Then 30mg Then Placebo	8
Neuropsych Screening	COMPLETED	A. Placebo Then 15mg Then 30mg	9
Neuropsych Screening	COMPLETED	B. 15mg Then Placebo Then 30mg	6
Neuropsych Screening	COMPLETED	C. 15mg Then 30mg Then Placebo	6
Neuropsych Screening	NOT COMPLETED	A. Placebo Then 15mg Then 30mg	1
Neuropsych Screening	NOT COMPLETED	B. 15mg Then Placebo Then 30mg	1
Neuropsych Screening	NOT COMPLETED	C. 15mg Then 30mg Then Placebo	2
First Intervention (1 Day)	STARTED	A. Placebo Then 15mg Then 30mg	9

1 to 10 of 63Source ClinicalTrials.gov

See all 63 participant flow

Adverse events15

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	cold symptoms / upper respiratory	Respiratory, thoracic and mediastinal disorders	Placebo	0	23	0
other	cold symptoms / upper respiratory	Respiratory, thoracic and mediastinal disorders	STX209 (15mg)	4	23	4
other	cold symptoms / upper respiratory	Respiratory, thoracic and mediastinal disorders	STX209 (30mg)	1	23	1
other	fatigue	General disorders	Placebo	3	23	3
other	fatigue	General disorders	STX209 (15mg)	4	23	4
other	fatigue	General disorders	STX209 (30mg)	1	23	1
other	increased appetite	General disorders	Placebo	1	23	1
other	increased appetite	General disorders	STX209 (15mg)	2	23	2
other	increased appetite	General disorders	STX209 (30mg)	0	23	0
other	overly energetic	General disorders	Placebo	2	23	2

1 to 10 of 15Source ClinicalTrials.gov

See all 15 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo	0	23
Total, all-cause mortality	STX209 (15mg)	0	23
Total, all-cause mortality	STX209 (30mg)	0	23
Total, other adverse events	Placebo	7	23
Total, other adverse events	STX209 (15mg)	11	23
Total, other adverse events	STX209 (30mg)	4	23
Total, serious adverse events	Placebo	0	23
Total, serious adverse events	STX209 (15mg)	0	23
Total, serious adverse events	STX209 (30mg)	0	23

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02278328

GET https://conductscience.org/api/trials/v1/NCT02278328/flow?page=2

API reference For AI assistants